Core Insights - VivoSim Labs, Inc. has validated its NAMkind™ liver and intestine models for predicting toxicity and side effect profiles of antibody drug conjugates (ADCs) [1][2] Group 1: ADC Toxicity and Validation - The NAMkind™ models are positioned as essential tools to differentiate anticancer activity from unwanted cytotoxicity in ADCs, which are widely used in oncology [2] - Testing of approved ADC therapies in NAMkind™ models shows a strong correlation with clinical results, effectively identifying liver toxicity in drugs like gemtuzumab ozogomicin and low liver toxicity in enfortumab vedotin [3] - The NAMkind™ intestine models can detect differential effects on epithelial cells, providing insights into the overall impact of ADCs on intestinal health [4] Group 2: Industry Impact and Adoption - The models are expected to enhance the success rate of ADC candidates in clinical settings by allowing partners to screen out toxicities during early development stages [5] - VivoSim's NAMkind models are recognized as cutting-edge in the field, with services now available in the US, Europe, Korea, and China, indicating a scaling capacity to meet global demand [6] - The anticipated shift towards non-animal testing methods following FDA announcements is expected to accelerate the adoption of human tissue models in drug development [7]